Scientists have developed a new amino acid that can be used to modify the 3D structure of therapeutic peptides. Insertion of the amino acid into bioactive peptides enhanced their binding affinity up to 40-fold. Peptides with the new amino acid could potentially become a new class of therapeutics.
In a new study that could ultimately lead to many new medicines, scientists have adapted a chemical approach to turn diseased cells into unique manufacturing sites for molecules that can treat a form of muscular dystrophy.
Cells attach so-called 'epigenetic' signals to their genome to select which part of their genetic information is used. Scientists have now systematically investigated the interplay between components of an epigenetic network and developed a mathematical model that describes how it operates. The results can be used to predict how cellular gene expression programs respond to drug treatment or other perturbations of the cellular environment.
About 50 years ago, electron microscopy revealed the presence of tiny blob-like structures that form inside cells, move around and disappear. But scientists still don't know what they do - even though these shifting cloud-like collections of proteins are believed to be crucial to the cell, and therefore could offer a new approach to disease treatment. Now, researchers are issuing a call to investigators to focus their attention on the role of these formations.
Scientists have developed a new amino acid that can be used to modify the 3-D structure of therapeutic peptides. Insertion of the amino acid into bioactive peptides enhanced their binding affinity up to 40-fold. Peptides with the new amino acid could potentially become a new class of therapeutics.
In a new study, scientists used an innovative technique to study how cells move in a three-dimensional matrix, similar to the structure of certain tissues, such as the skin. They discovered an entirely new type of cell movement whereby the nucleus helps propel cells through the matrix like a piston in an engine, generating pressure that thrusts the cell's plasma membrane forward.
Bochemists have identified the developmental on-off switch for Streptomyces, a group of soil microbes that produce more than two-thirds of the world's naturally derived antibiotic medicines. Their hope now would be to see whether it is possible to manipulate this switch to make nature's antibiotic factory more efficient.
Researchers have identified a gene that could help engineer drought-resistant crops. The gene, called OSCA1, encodes a protein in the cell membrane of plants that senses changes in water availability and adjusts the plant's water conservation machinery accordingly.